Arvinas, Inc. (ARVN)
ARVN Stock Price Chart
Explore Arvinas, Inc. interactive price chart. Choose custom timeframes to analyze ARVN price movements and trends.
ARVN Company Profile
Discover essential business fundamentals and corporate details for Arvinas, Inc. (ARVN) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
27 Sept 2018
Employees
430.00
Website
https://www.arvinas.comCEO
Randy Teel
Description
Arvinas, Inc. is a biopharmaceutical company in the clinical development stage, dedicated to identifying, advancing, and marketing innovative therapies designed to eliminate disease-causing proteins. The company's pipeline features several promising candidates. These include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader, currently in Phase I clinical trials, which specifically targets the androgen receptor (AR) protein to treat metastatic castration-resistant prostate cancer (mCRPC) in men. Another key PROTAC protein degrader is ARV-471, which targets the estrogen receptor protein for patients suffering from metastatic ER-positive/HER2-negative breast cancer. Furthermore, Arvinas is developing ARV-766, an investigational orally bioavailable PROTAC protein degrader also aimed at treating mCRPC in men. The company has strategic alliances with major pharmaceutical entities including Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., and Bayer AG. Founded in 2013, Arvinas, Inc. is headquartered in New Haven, Connecticut.
ARVN Financial Timeline
Browse a chronological timeline of Arvinas, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 5 Aug 2026
EPS estimate is -$0.24, while revenue estimate is $61.37m.
Earnings released on 12 May 2026
EPS came in at -$0.90 surpassing the estimated -$0.95 by +5.26%, while revenue for the quarter reached $15.60m , missing expectations by -6.09%.
Earnings released on 24 Feb 2026
EPS came in at -$1.10 falling short of the estimated -$0.55 by -100.00%, while revenue for the quarter reached $9.50m , missing expectations by -74.50%.
Earnings released on 5 Nov 2025
EPS came in at -$0.48 surpassing the estimated -$0.75 by +36.00%, while revenue for the quarter reached $41.90m , beating expectations by +12.44%.
Earnings released on 6 Aug 2025
EPS came in at -$0.84 surpassing the estimated -$0.87 by +3.45%, while revenue for the quarter reached $22.40m , missing expectations by -10.40%.
Earnings released on 1 May 2025
EPS came in at $1.14 surpassing the estimated -$0.86 by +232.56%, while revenue for the quarter reached $188.80m , beating expectations by +346.28%.
Earnings released on 11 Feb 2025
EPS came in at -$0.63 surpassing the estimated -$1.07 by +41.12%, while revenue for the quarter reached $59.20m , beating expectations by +39.19%.
Earnings released on 30 Oct 2024
EPS came in at -$0.68 surpassing the estimated -$0.88 by +22.73%, while revenue for the quarter reached $102.40m , beating expectations by +72.14%.
Earnings released on 30 Jul 2024
EPS came in at -$0.49 surpassing the estimated -$0.72 by +31.94%, while revenue for the quarter reached $76.50m , beating expectations by +40.26%.
Earnings released on 7 May 2024
EPS came in at -$0.97 surpassing the estimated -$1.48 by +34.46%, while revenue for the quarter reached $25.30m , missing expectations by -27.38%.
Earnings released on 27 Feb 2024
EPS came in at -$2.53 falling short of the estimated -$1.33 by -90.23%, while revenue for the quarter reached $43.10m , missing expectations by -12.58%.
Earnings released on 7 Nov 2023
EPS came in at -$1.18 surpassing the estimated -$1.52 by +22.37%, while revenue for the quarter reached $34.60m , missing expectations by -14.59%.
Earnings released on 8 Aug 2023
EPS came in at -$1.25 surpassing the estimated -$1.67 by +25.15%, while revenue for the quarter reached $54.50m , beating expectations by +85.37%.
Earnings released on 5 May 2023
EPS came in at -$1.54 falling short of the estimated -$1.46 by -5.48%, while revenue for the quarter reached $32.50m , beating expectations by +17.29%.
Earnings released on 23 Feb 2023
EPS came in at -$1.56 falling short of the estimated -$1.04 by -50.00%, while revenue for the quarter reached $38.00m , beating expectations by +6.39%.
Earnings released on 8 Nov 2022
EPS came in at -$1.24 falling short of the estimated -$0.98 by -26.53%, while revenue for the quarter reached $30.30m , missing expectations by -12.68%.
Earnings released on 4 Aug 2022
EPS came in at -$1.32 falling short of the estimated -$1.02 by -29.41%, while revenue for the quarter reached $31.30m , beating expectations by +26.46%.
Earnings released on 5 May 2022
EPS came in at -$1.20 falling short of the estimated -$0.85 by -41.18%, while revenue for the quarter reached $24.20m , missing expectations by -4.93%.
Earnings released on 28 Feb 2022
EPS came in at -$1.00 falling short of the estimated -$0.78 by -28.21%, while revenue for the quarter reached $26.30m , beating expectations by +86.02%.
Earnings released on 3 Nov 2021
EPS came in at -$0.94 falling short of the estimated $2.85 by -132.98%, while revenue for the quarter reached $9.28m , missing expectations by -96.22%.
Earnings released on 5 Aug 2021
EPS came in at -$1.03 falling short of the estimated -$0.84 by -22.62%, while revenue for the quarter reached $5.54m , beating expectations by +0.01%.
ARVN Stock Performance
Access detailed ARVN performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
